| Not Yet Recruiting | CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma NCT07383233 | Qi deng | Phase 1 |
| Not Yet Recruiting | Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products NCT07424157 | Seattle Children's Hospital | — |
| Not Yet Recruiting | Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy NCT07289087 | Associazione Qol-one | — |
| Not Yet Recruiting | Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond NCT07375628 | Karolinska University Hospital | — |
| Not Yet Recruiting | MB-CART2019.1 in Refractory Multiple Sclerosis NCT07178431 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Not Yet Recruiting | RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients NCT07296120 | The Cooper Health System | Phase 4 |
| Recruiting | DALY II Japan/MB-CART2019.1 for DLBCL NCT07288879 | Miltenyi Biomedicine GmbH | Phase 2 |
| Recruiting | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC NCT07246304 | TCRCure Biopharma Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 NCT07269587 | Ruijin Hospital | — |
| Recruiting | A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia NCT07198867 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Recruiting | Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy NCT07075523 | University of California, San Diego | — |
| Recruiting | Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL NCT07120633 | The Affiliated Hospital of Xuzhou Medical University | N/A |
| Not Yet Recruiting | Pre-emptive Anakinra for Cytokine Event Reduction NCT06703216 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 / Phase 2 |
| Recruiting | CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia NCT06622694 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS NCT06842589 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Not Yet Recruiting | Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-R NCT06935136 | Ruijin Hospital | N/A |
| Recruiting | Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE NCT06934447 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Recruiting | Coping Skills Training for Symptom Management and Daily Steps (Step Up) NCT06575712 | Duke University | N/A |
| Recruiting | Nutrition OUtReach In Systems of Healthcare NCT06802406 | University of Kansas Medical Center | N/A |
| Recruiting | Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia NCT06921980 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Not Yet Recruiting | CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors NCT06647329 | Mingzhi Zhang | Phase 1 |
| Recruiting | THRIVE-CAR-T Digital App NCT06665295 | Patrick C. Johnson, MD | N/A |
| Recruiting | Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies NCT06554951 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS NCT06553898 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Not Yet Recruiting | Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cel NCT06506396 | University of Modena and Reggio Emilia | — |
| Recruiting | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV NCT06508346 | The Children's Hospital of Zhejiang University School of Medicine | — |
| Recruiting | GPC3/Mesothelin-CAR-γδT Cells Against Cancers NCT06196294 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Active Not Recruiting | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus NCT06222853 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Unknown | Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients NCT05858684 | RenJi Hospital | EARLY_Phase 1 |
| Recruiting | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers NCT05779917 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Unknown | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy NCT05414162 | University Hospital, Bonn | — |
| Recruiting | ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy NCT05354973 | Stiftung Swiss Tumor Institute | — |
| Unknown | An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advance NCT05277987 | Shenzhen Fifth People's Hospital | EARLY_Phase 1 |
| Unknown | Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester NCT05099237 | Manchester University NHS Foundation Trust | N/A |
| Completed | Patient Reported Outcomes and Patient Education in Cellular Therapy Patients NCT04853277 | Dartmouth-Hitchcock Medical Center | N/A |
| Unknown | CAR T-CELL Therapy Educational Video Trial NCT04280133 | Massachusetts General Hospital | N/A |
| Completed | Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT NCT07236151 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Exercise as an Immune Adjuvant for Allogeneic Cell Therapies NCT06643221 | University of Arizona | EARLY_Phase 1 |